(Q34661731)

3 August 2017

title

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study (English)

1 reference

relapsing-remitting multiple sclerosis

3 August 2017

0 references

0 references

1 reference

2

Bernd C Kieseier

1 reference

3 August 2017

4

Laura J Balcer

1 reference

3 August 2017

1

Peter A Calabresi

1 reference

3 August 2017

10

Serena Hung

1 reference

3 August 2017

9

Ali Seddighzadeh

1 reference

3 August 2017

Douglas L Arnold

3

1 reference

3 August 2017

Alexey Boyko

5

1 reference

3 August 2017

Jean Pelletier

6

1 reference

3 August 2017

Shifang Liu

7

1 reference

3 August 2017

Ying Zhu

8

1 reference

3 August 2017

Aaron Deykin

11

1 reference

3 August 2017

ADVANCE Study Investigators

12

1 reference

3 August 2017

publication date

30 April 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

657-665

1 reference

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

PEGylation: an approach for drug delivery. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

PEG-modified biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

PEGylation of Interferon-β-1a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Axonal degeneration in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Multiple sclerosis--the plaque and its pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970068-7

7 January 2021

10.1016/S1474-4422(14)70068-7

Identifiers

DOI

1 reference

3 August 2017

1 reference